Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Equity Average: 2020-2025

Historic Equity Average for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $50.4 million.

  • Mereo BioPharma Group's Equity Average fell 33.34% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.4 million, marking a year-over-year decrease of 33.34%. This contributed to the annual value of $55.8 million for FY2024, which is 9.39% up from last year.
  • Mereo BioPharma Group's Equity Average amounted to $50.4 million in Q3 2025, which was down 11.80% from $57.1 million recorded in Q2 2025.
  • Mereo BioPharma Group's Equity Average's 5-year high stood at $75.6 million during Q3 2024, with a 5-year trough of -$99.6 million in Q2 2021.
  • In the last 2 years, Mereo BioPharma Group's Equity Average had a median value of $60.5 million in 2025 and averaged $59.7 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 154.01% in 2021, then crashed by 33.34% in 2025.
  • Mereo BioPharma Group's Equity Average (Quarterly) stood at $17.0 million in 2021, then skyrocketed by 128.63% to $38.9 million in 2022, then reached $66.8 million in 2024, then slumped by 33.34% to $50.4 million in 2025.
  • Its Equity Average was $50.4 million in Q3 2025, compared to $57.1 million in Q2 2025 and $60.5 million in Q1 2025.